Introduction
Umbilical cord blood transplantation (UCBT) has been demonstrated as a viable alternate source for allogeneic stem cell transplantation (AlloSCT). We and others have helped to establish myeloablative UCBT as a successful treatment modality for specific pediatric malignant and non-malignant diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Several reports also attest to the validity of this source of hematopoietic stem cells following myeloablative therapy in adult recipients with various hematological disorders/malignancies. [11] [12] [13] [14] [15] [16] [17] Conventional UCBT utilizes a total body irradiation or a busulfan-based myeloablative conditioning regimen, which carries a high risk of significant morbidity and mortality. 18, 19 Several investigators have shown the potential of non-myeloablative or reduced intensity (RI) conditioning followed by AlloSCT to reduce regimen-related morbidity, regimen-related mortality (RRM) and potentially future late effects in patients with both malignant and nonmalignant disorders. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] A recent review by our group has summarized the results to date following RI conditioning for allogeneic stem cell transplantation (RI-AlloSCT). 35 Recently, successful engraftment has been demonstrated after reduced intensity UCBT (RI-UCBT) in adult recipients. [36] [37] [38] [39] However, there is a paucity of data regarding RI-UCBT in children and adolescent recipients.
We hypothesized that RI-UCBT in children and adolescent recipients will result in rapid neutrophil and platelet recovery and greater than 50% stable mixed-donor chimerism in children and adolescent recipients with both malignant and non-malignant diseases. In this report, we present the preliminary results, including donor chimerism, toxicity, engraftment, graft-versus-host disease (GVHD), infection, and survival in a group of 21 children and adolescents with either malignant or non-malignant disorders, who received RI conditioning followed by UCBT.
Materials and methods

Eligibility
Patients p21 years of age with both malignant and nonmalignant disorders were eligible for RI conditioning followed by UCBT; patients were eligible if they lacked a matched family donor, a matched unrelated adult donor (9-10/10 human leukocyte antigen (HLA) match) or if their disease status required emergent AlloSCT and they could not wait 2-3 months for a matched unrelated adult hematopoietic stem cell donor. Patients were eligible if they had a fully matched or a one or two antigenmismatched unrelated cord blood (CB) unit with a minimum of cryopreserved cell dose X2 Â 10 7 total nucleated cells (TNCs) per kilogram. All patients required a 450% Lansky (p16 years) or Karnofsky (416 years) performance status before study entry. Option for standard myeloablative transplant was also provided to all patients/ parents. All patients/parents signed informed consents and assents when applicable. All informed consents and assents were approved by the Institutional Review Board of Columbia University Medical Center. All research protocols were in compliance with the Declaration of Helsinki Principle.
Unrelated donor selection and HLA typing HLA-A and HLA-B antigen typing was performed by low resolution molecular testing, and HLA-DRB1 allele typing was determined by hybridization of polymerase chain reaction (PCR)-amplified DNA with sequence-specific oligonucleotide probes. 40 Confirmatory typing was performed at Columbia University Medical Center. Priority was given to select the most closely matched donor unitrecipient pair, and subsequently the unit with the largest nucleated cell dose was selected. Transplants were classified as HLA mismatched with 1 or 2 differences if disparities were detected in HLA-A, HLA-B antigens or HLA-DRB1 alleles.
Reduced conditioning regimen An RI conditioning regimen was defined as fludarabinebased regimens with a busulfan dose of p8 mg/kg or a cyclophosphamide dose of p120 mg/kg7etoposide (900 mg/m 2 ). RI conditioning regimens were disease protocol driven. [41] [42] [43] [44] the cryopreserved umbilical cord blood (UCB) unit was placed in a sterile bag and then thawed in a 381C water bath with gentle agitation. After thawing, an equal volume of dextran/albumin solution was added over 10 min, centrifuged at 400 g for 15 min at 101C and the supernatant removed. The cell pellet was re-suspended in dextran/albumin and immediately infused into the patient over 30-60 min. CD34 quantitation was performed by the ProCount method (Becton Dickinson, San Jose, CA, USA). The percent CD34/45 was multiplied by the automated white blood cell count (WBC) to obtain the total CD34 in the product. The final (post-manipulation) WBC was used to enumerate the absolute number of CD34 cells infused.
GVHD prophylaxis and grading
Acute GVHD (aGVHD) prophylaxis consisted of tacrolimus starting at 0.03 mg/kg/day as continuous i.v. infusion or 0.12 mg/kg orally (p.o.) twice a day with dosage adjustment to maintain blood levels between 5 and 20 ng/ ml and mycophenolate mofetil (MMF) at 15-30 mg/kg q 6-12 h either p.o. or i.v., as we have described previously. 45 Tacrolimus was started either on first day of conditioning regimen or day À1 and MMF began on day þ 1. Tacrolimus and/or MMF were tapered if patients had pgrade II aGVHD on day þ 30 for malignant diseases and day þ 180 for non-malignant diseases. 45 aGVHD and chronic GVHD (cGHVD) were graded according to Seattle criteria. 46 All patients who achieved any level of donor chimerism were considered at risk for developing aGVHD. Only patients with sustained engraftment of donor hematopoiesis and surviving for more than 100 days after transplant were evaluated for the development of cGVHD.
Supportive care
All patients received sargramostim (250 mcg/m 2 /day) i.v. daily from day 0 until the WBC reached X300/mm 3 Â 2 days, and then were switched to filgrastim (10 mcg/kg/day) either i.v. or subcutaneously until an absolute neutrophil count (ANC) of X2500/mm 3 was achieved for 3 days as we described previously. 47 Herpes simplex prophylaxis consisted of acyclovir (250 mg/m 2 ) i.v. q 8 h from day À5 until engraftment and pgrade II mucositis. Pneumocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole until day À2 and then resumed three times weekly after myeloid engraftment. Patients unable to tolerate trimethoprim/sulfamethoxazole received i.v. pentamidine prophylaxis every 2 weeks. Fungal prophylaxis consisted of liposomal amphotericin B (3 mg/kg/day) i.v. starting on day 0 through day þ 100 as we described previously. 48 Cytomegalovirus (CMV) prophylaxis was administered as we have recently described. 49 Engraftment and chimerism Neutrophil recovery was defined as an ANC of 500/mm 3 for 3 consecutive days. Platelet recovery was defined as a platelet count of 20 000/mm 3 independent of platelet transfusions for at least 7 days. Primary myeloid graft failure was defined as failure to achieve a donor-derived ANC X500/mm 3 by day þ 42 and/or p50% whole-blood donor chimerism by day þ 60 in all except immune deficiency patients. In patients with T cell or combined immune deficiency, primary graft failure was defined as p50% T-cell (CD3) donor chimerism by day þ 180. Donor myeloid and/or lymphoid chimerism was measured on days þ 30, 60, 100, 180 and 365 after transplant. The percent donor chimerism was determined by quantifying fluorescent-labeled PCR products from donor and recipient alleles at short tandem repeat loci. Donor chimerism was determined for whole-blood and cell subsets as required by the individual disease protocol. Cell subsets were isolated using Miltenyi magnetic particles. The purity of each subset was determined by flow cytometry. 
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Statistics Probabilities of neutrophil recovery, platelet recovery, aGVHD and cGVHD, regimen-related death (non-relapse mortality), and survival were estimated using the KaplanMeier method. 52 Poor-risk patients were defined as patients with malignant disease with refractory disease and/or complete response (CR) 3 or beyond. The remaining patients were classified as average risk. Relapse was defined by morphological and/or radiological evidence of malignant disease in any site and was considered as time interval between UCBT and relapse, with censoring at death or complete remission. Transplant-related mortality (TRM) was defined as all causes of non-relapse death before 100 days after transplant. Overall survival (OS) was the time between transplantation and death due to any cause or between transplantation and the day of last follow-up. The median survival of this patient group was estimated with a 95% confidence interval (CI). Kaplan-Meier curves were used to summarize survival. Cumulative incidence functions were used to summarize time to engraftment and time to GVHD. Univariate analysis of Cox proportional hazards model was used to evaluate the impact of HLA typing, CD34 and TNC dose on survival.
Results
Demographics
From May 2001 to March 2006, 21 patients with malignant and non-malignant diseases received RI conditioning followed by UCBT. Characteristics of the patients are summarized in Table 1 . The median age was 9 years (0.33-20 years) and the median follow-up was 1.7 years (0.4-5.5). There were 14 males and 7 females. Fourteen patients were transplanted for malignant disease:
, non-Hodgkin's disease n ¼ 2 (one anaplastic large cell lymphoma in partial response and one diffuse large B-cell lymphoma with SD), chronic myelogenous leukemia (CML) (chronic phase n ¼ 1), acute myelogenous leukemia (AML) n ¼ 2 (CR1 n ¼ 1, CR2 n ¼ 1), secondary AML (CR1 n ¼ 1) and myelodysplastic syndrome (MDS) n ¼ 3 (two primary, one therapy related). Seven patients were transplanted for non-malignant diseases, all with SD: hemophagocytic lymphohistiocytosis (HLH) n ¼ 2, Wiskott Aldrich syndrome n ¼ 1, b-thalassemia n ¼ 1, severe aplastic anemia n ¼ 1 and severe combined immunodeficiency (SCID) n ¼ 2.
UCB donors and cell dose
One patient received a 6/6 related CB unit and two patients received a 6/6 matched unrelated UCB unit. The remainder received 1-2 antigen-mismatched unrelated UCB units (5/6 n ¼ 5 and 4/6 n ¼ 13 /kg (prethaw) of recipient weight, six patients received o2 Â 10 7 TNC/kg due to discrepancy between pre-and post-thaw cell count; post-thaw TNC in all CB units was lower than pre-freeze, the range of discrepancy was from 10 to 70% (Table 1) .
Engraftment and chimerism
The median time to neutrophil recovery was 17.5 days (9-45) (Table 2; Figure 1a ) and the median time to platelet engraftment was 52 days (25-170) (Table 2; Figure 1b ) for all 14 evaluable patients. The six patients who had primary graft failure demonstrated autologous reconstitution. The outcome of patients with primary graft failure is described in Table 3 . Donor chimerism was achieved in 14 of the 20 evaluable patients. One patient died secondary to CMV pneumonitis on day þ 13; this patient was not evaluable. Of the 14 patients who engrafted, one patient with Hodgkin's disease died on day þ 79 of PD with 55% donor chimerism. The average donor chimerism of all patients alive on day þ 60 was 61% (n ¼ 20) and on day X þ 180 was 94% (n ¼ 9, excluding six primary graft failures) (Figure 2 ). GVHD Four of 13 evaluable patients after RI-UCBT developed grade II to grade IV aGVHD, 1 of 4 developed grade III/IV aGVHD of the skin and intestine and one patient (1/16) developed de novo extensive cGVHD. The probability of developing grade II to grade IV and grade III to grade IV aGVHD was 28.6% (CI 95 : 4.9-52.2) and 9.1% (CI 95 : 0-26.1), respectively (Figure 3a) , and the probability of cGVHD was 16.7% (CI 95 : 0-46.5; Figure 3b ).
Grade III to grade IV non-hematological toxicities
Two patients developed grade IV non-hematological, noninfectious toxicity. One patient developed transient elevation of liver transaminases during busulfan conditioning, which resolved spontaneously, and one patient developed grade IV hearing loss secondary to aminoglycoside ototoxicity. Two patients developed grade III hematuria, which resolved with supportive care, and one patient developed grade III pulmonary toxicity secondary to cGVHD and therapy-related toxicity. Only one of the 21 patients developed grade III nephrotoxicity, which was reversible when the nephrotoxic agents were discontinued.
During the study period, 39 incidents of grade III and grade IV bacteremia/sepsis were observed: coagulase negative staphylococcus sp n ¼ 16, Gram-negative bacteria n ¼ 11 and other Gram-positive bacteria n ¼ 12. In each incident the patients fully recovered with appropriate antimicrobial therapy. Viral infections were less common but did occur. Four patients were diagnosed with upper respiratory tract viral infections. Three cases of respiratory syncytial virus were treated with aerosolized ribavirin and resolved without progressing to lower tract infection. One patient with grade III pulmonary toxicity and GVHD of the lung had persistently positive influenza-A treated with oseltamivir that never cleared before death. Three patients developed CMV infection/disease requiring therapy. Two patients developed CMV infection (reactivation) that responded to induction followed by maintenance therapy with ganciclovir. A third patient with SCID developed de novo CMV pneumonitis early in the transplant period and succumbed to this infection. Two patients developed disseminated adenovirus infection. One patient who had refractory aGVHD was treated with 1 mg/kg of cidofovir three times a week and had not cleared at the time of death, and in the second patient adenovirus was isolated postmortem. One patient developed disseminated atypical mycobacterium and was successfully treated with a fourdrug regimen of azithromycin, levofloxacin, rifampin and amikacin. One patient with cGVHD of the lung developed pulmonary aspergillosis and died.
Survival
The 5-year OS for all 21 patients was 59.8% (CI 95 : 37.9-81.6; Figure 4a ). The 5-year OS for patients with malignant disease was 56.2% (CI 95 : 29.8-82.7; Figure 4a ). The 5-year OS for patients with average-risk malignancy (n ¼ 9) was 77.8% (CI 95 : 50.6-100), which was significantly better than patients with poor-risk malignancy (n ¼ 5) which was 22.2% (CI 95 : 0-55.1) (P ¼ 0.03; Figure 4b ). The probability of 5-year OS for patients with non-malignant disease (n ¼ 7) was 68.6% (CI 95 : 32.0-100; Figure 4a ). Univariate analysis did not demonstrate any impact of TNC, CD34 cell dose and HLA matching of UCB on OS (Table 4) .
RRM was low; one patient with SCID died of RRM/ viral pneumonitis at day þ 13 after RI-UCBT. Five patients died of disease; two with refractory persistent disease and three relapsed after RI-UCBT. The two patients with persistent refractory disease before transplantation engrafted after RI-UCBT, but succumbed to their disease at days þ 77 and þ 212, respectively. Two patients were in CR after engraftment but subsequently relapsed, and succumbed to RRM, veno-occlusive disease, during a second but myeloablative transplant. Two additional patients died in CR secondary to GVHD-related complications. Only one mortality secondary to AML relapse was observed among six patients with primary graft failure.
Discussion
UCB contains sufficient concentrations of competent hematopoietic stem cells to reconstitute pediatric and adult patients following full myeloablation. 1, 13, 18, 53 In most studies reported to date, TNC dose per kilogram has been the single most important factor influencing time to hematological reconstitution. We and others 10, 13 have demonstrated that CD34 cell dose of UCB significantly affects OS following myeloablative UCBT. In the current study of RI-UCBT, median cell dose was 3.5 Â 10 7 TNC/ kg. The median time for myeloid engraftment was 17.5 days and median time for platelet engraftment was 52 days. This compares favorably with large multi-institutional series of UCBT following myeloablative conditioning regimens, where myeloid recovery median times ranged from 25 to 30 days 18, 19 and median platelet recovery time was 56 days to reach a platelet count of 20 000/mm 318 to 71 days to reach 50 000/mm 3 . 19 A recently reported large series of myeloablative UCBT in adults showed a median time to myeloid engraftment of 27 days and a median time to platelet engraftment of 60 days. 15 The largest series of single-unit RI-UCBT in adult patients report time to myeloid engraftment of 17.5-20 days and a time to platelet engraftment of 39 days; results that are almost similar to our current study in pediatric recipients. 37, 39 Wagner et al.
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demonstrated that the CD34 cell dose per kilogram is a significant variable for the rate of engraftment. However, in this study with a small number of patients, TNC and CD34 cell dose did not appear to influence the percentage of mixed donor chimerism and OS. We demonstrated that RI conditioning in pediatric recipients is associated with a high degree of mixed donor chimerism in most pediatric diseases. However, there were six episodes of graft failure in our study. Thirteen evaluable engrafted patients achieved X90% donor chimerism by day þ 90. If relapse did not occur, sustained chimerism was observed (98% at day þ 365). Five of the six patients who experienced graft failure had diseases that were not treated with chemotherapy or immunosuppressive therapy (chemonaı¨ve) before RI conditioning (CML, b-thalassemia, HLH and MDS). The lack of significant cytotoxic and/or immunosuppressive pretreatment in these patients may signify that patients with these specific diseases will likely benefit from more intense conditioning regimens. [54] [55] [56] In fact, four of these patients achieved full-donor chimerism after undergoing a second, but this time myeloablative UCBT. Our protocols have been modified to provide patients who have undergone minimal cytotoxic pretreatment (CML, b-thalassemia, MDS and HLH) with increased intensity of conditioning by increasing the dose of busulfan from 8 mg to 16 mg/kg and replacing R-ATG with alemtuzumab (54 mg/m 2 ). Cell dose may also influence engraftment and TRM in unrelated UCB transplant. Gluckman et al. 57 recently reported that cell dose and HLA matching play a significant role in engraftment and that the requirements are different for malignant versus non-malignant diseases. Eurocord analyzed 268 patients transplanted for non-malignant conditions and reported that a minimum of 3.5 Â 10 7 nucleated cells per kilogram are needed at the time of infusion. While HLA mismatch also plays a major role in engraftment, survival and GHVD, this is also partially overcome by a higher cell dose. 57 Myeloablative UCBT is associated with 35-50% incidence of TRM. 1, 13, 18, 53 In the current study, incidence of TRM was 14%; two patients died secondary to aGVHDand cGVHD-related complications, respectively, and one patient died secondary to viral infection on day þ 13. This suggests that RI conditioning may reduce TRM following UCBT. However, regimen-related morbidity was high, and RI conditioning does not seem to have reduced the number of infection-associated complications. We report 39 cases of bacteremia as well as several cases of persistent viral infection. The frequency of these infections may be explained by delayed immune reconstitution associated with UCBT and peri-transplant immunosuppression. 58 In a recent study of RI-UCBT in adults receiving CMV preemptive therapy, the incidence of CMV reactivation and CMV disease was 55 and 16%, respectively. 59 We postulate, however, that our aggressive CMV and fungal prophylaxis regimens 48, 49 led to a low incidence of CMV and fungal infections.
We report a 28% probability of Xgrade II aGVHD and a 16% probability of developing cGVHD following RI-UCBT. This compares favorably with reported rates of 40.6% Xgrade II aGHVD and 50.7% cGHVD in myeloablative UCBT in adults, 15 and similar to rates of 27-40% Xgrade II aGVHD and 10-40% cGVHD in RI-UCBT in adults. 37, 39 In our original reports, the incidence of grade II to grade IV aGVHD ranged between 40 and 60% following myeloablative unrelated HLA 2-3 antigen disparate UCBT in pediatric recipients. 2, 3 Couriel et al.
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and Mielcarek et al. 61 have suggested a reduced incidence of aGVHD in adult recipients following RI-AlloSCT. Our results are consistent with these findings of potentially reduced aGVHD following RI conditioning and UCBT in pediatric recipients. However, a randomized study will be required to determine if there is a significant difference in grade II to grade IV aGVHD in pediatric recipients following RI versus myeloablative unrelated UCBT.
Our survival rates, although preliminary, demonstrate that RI-UCBT is a promising transplant option in children and adolescents, particularly in those patients with malignancies that are not far advanced (CR, partial response or SD), as the process of graft versus malignancy effect seems to be too slow to overcome a high-risk progressive malignancy. RI-UCBT should be considered for pediatric patients whose condition at the time of transplantation places them at a high risk of toxicity (co-morbidities) from myeloablative transplantation. Studies are ongoing to determine the place of RI-UCBT in standard-risk pediatric hematological malignancies, 62 pediatric solid tumors 63 and selected non-malignant diseases. 34 The optimal intensity of conditioning for individual diseases, particularly CML, HLH and b-thalassemia, remains to be elucidated.
In summary, we have successfully demonstrated a high degree of mixed donor chimerism and myeloid engraftment in children with both malignant and non-malignant disease following RI-UCBT. These results, however, include a heterogeneous group of patients and different RI conditioning regimens. These preliminary results should be interpreted with caution until larger groups of children with a homogenous diagnosis and RI regimen are utilized. Additionally, longer follow-up is required to more accurately assess cGVHD, survival and late effects. The role of graft versus tumor effect following RI-AlloSCT in children with selected malignancies needs further investigation. Lastly, to more accurately determine the difference, if any, of late long-term effects in pediatric recipients following RI-UCBT requires a larger cohort of patients with much longer follow-up. 
